Clinical trial
GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to…
NCT00414622 · CoMentis, Industry · Completed
Key facts
| NCT number | NCT00414622 |
|---|---|
| Title | GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease |
| Official title | A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease |
| Lead sponsor | CoMentis, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Alzheimer Disease |
| Intervention type | Drug |
| Interventions | DMXB-A |
| Enrollment | 60 |
| Start date | Nov 1, 2006 |
| Completion | Apr 1, 2007 |
| First posted | Dec 21, 2006 |
| Last update posted | Apr 19, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: